Antibody-targeted photodynamic therapy
Antibody-targeted photodynamic therapy
复制标题
DOI：
10.1016/s0002-9394(03)00675-5
复制
发表时间：
2003-12-01
影响因子：
4.2
通讯作者：
Glickman, RD
中科院分区：
文献类型：
--
作者：
Mayo, GL;Melendez, RF;Glickman, RD
目得：评价维替泊芬（Visudyne，Parkedale Pharmaceuticals，罗切斯特，明尼苏达州，美国）与抗血管内皮生长因子抗体偶联的可行性。设计：实验研究。检测了维替泊芬及其偶联物的荧光激发、发射光谱。将表达血管内皮生长因子的鼠内皮细胞与盐水、维替泊芬或缀合物一起孵育，然后进行激光暴露或不进行激光暴露。通过台盼蓝拒染法评估1小时和24小时的细胞活力。结果：该偶联物的荧光激发-发射光谱与维替泊芬的荧光激发-发射光谱相似。激光照射后，偶联物处理的细胞中的细胞活力在1小时时降低至6%（P
PURPOSE: To assess the feasibility of conjugation of verteporfin (Visudyne, Parkedale Pharmaceuticals, Rochester, Minnesota, USA) to antibody against vascular endothelial growth factor.DESIGN: Experimental study.METHODS: Rabbit antimouse vascular endothelial growth factor polyclonal antibody was conjugated to verteporfin. Fluorescence excitation,emission spectra of verteporfin and conjugate were examined. Vascular endothelial growth factor-expressing murine endothelial cells were incubated with saline, verteporfin, or conjugate, followed by laser exposure or no laser exposure. Cell viability at 1 and 24 hours was assessed via trypan blue exclusion. Results were analyzed by two,way analysis of variance with replication and the Bonferroni multiple comparison test.RESULTS: The fluorescence excitation-emission spectrum of the conjugate was similar to that of verteporfin. After laser exposure, cell viability in conjugate,treated cells was reduced to 6% at 1 hour (P